Therapy News and Research

RSS

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

During the month of August, people with a certain type of psoriasis have the chance to access free medicine through Avenue to Access. The program is designed to help individuals with mild-to-moderate stable plaque psoriasis access to a free prescription-size tube of ZITHRANOL-RR (anthralin, 1.2%) rapid release microcrystalline encapsulated cream.

16 Aug 2010

Use of estrogen alone does not increase lung cancer mortality in postmenopausal women: Study

Use of estrogen alone did not increase lung cancer mortality in postmenopausal women, according to a study published online August 13 in The Journal of the National Cancer Institute. In the Women's Health Initiative (WHI) trial, which consisted of several clinical trials on postmenopausal women, one study showed women with previous hysterectomy taking combined estrogen plus progestin therapy had a statistically significant increase in lung cancer mortality, but not incidence. Other studies with combined hormone therapy have had conflicting results. But the influence of estrogen alone was unclear.

16 Aug 2010

Mathematical model projects potential impact of current tools fighting malaria in Africa

Current tools for combating malaria, such as artemisinin-based combination therapy (ACT) and increasing coverage of long-lasting insecticide treated nets (LLINs) insecticide-treated bednets (ITN) "could dramatically reduce the burden of malignant malaria on parts of Africa if a comprehensive, sustained intervention programme were in place," according to a study published this week in PLoS Medicine, CORDIS News reports.

16 Aug 2010

Research Roundup: Disabled Medicare Enrollees' challenges; Increasing ER visits; costs/benefits of Part D

Health Affairs: Medicare Doesn't Work As Well For Younger, Disabled Beneficiaries As It Does For Older Enrollees - This paper examines "how well Medicare works for [the 8 million] nonelderly disabled beneficiaries compared to the elderly, based on findings from a nationally representative survey of noninstitutionalized Medicare beneficiaries conducted in 2008 by the Kaiser Family Foundation."

16 Aug 2010

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs. But an international team of scientists, headed by researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine, reports in the August 15 issue of Genes & Development that they have discovered a new signaling pathway between GBM cells - one that, if ultimately blocked or disrupted, could significantly slow or reduce tumor growth and malignancy.

16 Aug 2010

CD31 positive cells have potential for treating peripheral artery disease: Research

Isolating cells from a patient's blood or bone marrow that nourish blood vessels may be a safer and less arduous route to treatment of cardiovascular disease than obtaining rare stem cells, according to research from Emory University School of Medicine. In recent clinical trials, doctors in several countries have tested the ability of a patient's bone marrow cells to repair damage, such as heart attacks and peripheral artery disease, created by problems of blood flow.

16 Aug 2010

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

A significant milestone has been reached in the development of a new therapy for patients suffering from coronary artery disease. On July 27, 2010 the BIOTRONIK DREAMS (Drug Eluting Absorbable Metal Scaffold) was successfully implanted in the first patient by Prof. Dr. Michael Haude at the Lukaskrankenhaus in Neuss, Germany as part of the first-in-man clinical study BIOSOLVE-I.

13 Aug 2010

Electromed prices 1,700,000 shares of initial public offering

Electromed, Inc., which is a leader in developing innovative airway clearance therapy products for use by patients with compromised pulmonary function, today announced pricing of its initial public offering of 1,700,000 shares of common stock at a price of $4.00 per share, before underwriting discounts and commissions.

13 Aug 2010

Management of therapy-resistant schizophrenia

The psychotic symptoms of up to 30% of schizophrenic patients do not respond adequately to treatment with antipsychotic drugs, other than clozapine. These refractory patients are generally among the most disabled of all people with schizophrenia and require special assessment and treatment.

13 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

13 Aug 2010

Hana Biosciences second-quarter net loss decreases to $6.3 million

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and six months ended June 30, 2010, and provided a corporate update.

13 Aug 2010

UMass Memorial selects McKesson's CytoCare robot to automate compounding of hazardous IV drugs

UMass Memorial Medical Center in Massachusetts has selected the CytoCare™ robot from McKesson to automate the compounding of intravenous (IV) drugs. The robotic technology will enable the 830-bed facility to more safely prepare hazardous IVs, protecting both their patients and their staff from exposure risks.

13 Aug 2010

Benvenue Medical commences treatment in U.S. with Blazer Vertebral Augmentation System

Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced today that it has treated the first patient in the United States with the Blazer Vertebral Augmentation System - a new device for the treatment of vertebral compression fractures (VCFs). The case was performed by Francis Facchini, M.D., partner, VIR Chicago, at Adventist GlenOaks Hospital in Glendale Heights, Illinois.

13 Aug 2010

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

In a move likely to secure its place as a leading provider of medical radiation countermeasures, Humanetics Corporation today announced that it has secured exclusive worldwide licenses to two new treatments that provide short and long-term post-exposure protection from ionizing radiation acquired during a terrorist act, nuclear or radiological attack or accident, as part of cancer radiotherapy or even during routine diagnostic CT scans.

13 Aug 2010

Neurologix second-quarter net loss increases to $4.5 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Kibow to support KDAE week for educating policymakers about kidney disease

Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).

13 Aug 2010

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.

13 Aug 2010

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

Study finds Olaparib can reduce tumor size in ovarian cancer women

Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.

13 Aug 2010

Therapy News and Research

Avenue to Access provides free prescription-size tube of ZITHRANOL-RR to stable plaque psoriasis patients

Use of estrogen alone does not increase lung cancer mortality in postmenopausal women: Study

Mathematical model projects potential impact of current tools fighting malaria in Africa

Research Roundup: Disabled Medicare Enrollees' challenges; Increasing ER visits; costs/benefits of Part D

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

CD31 positive cells have potential for treating peripheral artery disease: Research

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

Electromed prices 1,700,000 shares of initial public offering

Management of therapy-resistant schizophrenia

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

Hana Biosciences second-quarter net loss decreases to $6.3 million

UMass Memorial selects McKesson's CytoCare robot to automate compounding of hazardous IV drugs

Benvenue Medical commences treatment in U.S. with Blazer Vertebral Augmentation System

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

Neurologix second-quarter net loss increases to $4.5 million

Kibow to support KDAE week for educating policymakers about kidney disease

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Study examines impact of microvascular decompression surgery for type 2 diabetes

Study finds Olaparib can reduce tumor size in ovarian cancer women

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News